David G Pfister

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA
    BMC Genet 3:22. 2002
  2. ncbi request reprint Clinical practice. Surveillance strategies after curative treatment of colorectal cancer
    David G Pfister
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 350:2375-82. 2004
  3. pmc Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial
    David G Pfister
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:2565-70. 2010
  4. ncbi request reprint Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm
    David G Pfister
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 24:1072-8. 2006
  5. pmc Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
  6. ncbi request reprint Predictors of outcome for advanced-stage supraglottic laryngeal cancer
    Ian Ganly
    Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 31:1489-95. 2009
  7. ncbi request reprint Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy
    Michelle L Klem
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Int J Radiat Oncol Biol Phys 70:1100-7. 2008
  8. pmc A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    Cancer 119:1823-31. 2013
  9. doi request reprint Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 82:291-8. 2012
  10. doi request reprint Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 31:465-9. 2008

Research Grants

Detail Information

Publications66

  1. pmc Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA
    BMC Genet 3:22. 2002
    ..We used comparative genomic hybridization (CGH) to screen for the genetic aberrations in 71 patients with head and neck squamous cell carcinoma and stratified the findings by the status of tobacco/alcohol exposure...
  2. ncbi request reprint Clinical practice. Surveillance strategies after curative treatment of colorectal cancer
    David G Pfister
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 350:2375-82. 2004
  3. pmc Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial
    David G Pfister
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 28:2565-70. 2010
    ..To determine whether acupuncture reduces pain and dysfunction in patients with cancer with a history of neck dissection. The secondary objective is to determine whether acupuncture relieves dry mouth in this population...
  4. ncbi request reprint Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm
    David G Pfister
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 24:1072-8. 2006
    ..Cetuximab has activity in squamous cell carcinoma and enhances both chemotherapy and radiotherapy. We conducted a pilot phase II study of a new combined-modality paradigm of targeted therapy (cetuximab) with chemoradiotherapy...
  5. pmc Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 82:299-307. 2012
    ..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment...
  6. ncbi request reprint Predictors of outcome for advanced-stage supraglottic laryngeal cancer
    Ian Ganly
    Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 31:1489-95. 2009
    ..The objective of this study was to report our experience in the management of patients with advanced-stage supraglottic laryngeal carcinoma and to identify factors predictive of outcome...
  7. ncbi request reprint Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy
    Michelle L Klem
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    Int J Radiat Oncol Biol Phys 70:1100-7. 2008
    ..With conventional techniques, significant toxicity can develop. Intensity-modulated radiotherapy (IMRT) has the potential to minimize the toxicity...
  8. pmc A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    Cancer 119:1823-31. 2013
    ..The authors conducted a phase 1 study to evaluate the addition of oral everolimus to cisplatin and docetaxel as induction chemotherapy for head and neck cancer...
  9. doi request reprint Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience
    Jeremy Setton
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 82:291-8. 2012
    ..To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC)...
  10. doi request reprint Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer
    Ramesh Rengan
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 31:465-9. 2008
    ..To examine the long-term neck failure outcome in patients with advanced head and neck cancer treated on larynx/organ preservation protocols at Memorial Sloan-Kettering Cancer Center...
  11. doi request reprint A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
    Matthew G Fury
    Department of Medicine, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York
    Int J Radiat Oncol Biol Phys 87:479-86. 2013
    ..Preclinically, inhibition of mTORC1 with everolimus sensitizes cancer cells to cisplatin and radiation...
  12. pmc Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases
    Amita Shukla-Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1837-44. 2012
    ..The goal of this study was to assess the prognostic value of pretreatment DCE-MRI in head and neck squamous cell carcinoma (HNSCC) patients with nodal disease undergoing chemoradiation therapy or surgery...
  13. pmc Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx
    Jeannette Marie S Matsuo
    Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 238:412-21; discussion 421-2. 2003
    ..To determine the impact of clinical nodal stage on distant metastasis (DM) in patients with squamous cell carcinoma of the larynx (SCCL)...
  14. doi request reprint Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes
    Benjamin H Lok
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1851-7. 2012
    ..To analyze the effect of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) on treatment outcomes in patients treated with definitive intensity-modulated radiation therapy (IMRT) for oropharyngeal cancer (OPC)...
  15. pmc Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Thyroid 23:593-9. 2013
    ..In thyroid cancer cell lines, romidepsin increases expression of both thyroglobulin and the sodium iodide symporter messenger RNAs, suggesting the possibility of improved iodine concentrating ability of RAI-resistant tumors...
  16. doi request reprint Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities
    Bradford S Hoppe
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Radiat Oncol Biol Phys 72:763-9. 2008
    ..To evaluate long-term outcomes and toxicity in patients with unresectable paranasal sinus carcinoma treated with radiotherapy, with or without chemotherapy...
  17. pmc Sharing a diagnosis of HPV-related head and neck cancer: the emotions, the confusion, and what patients want to know
    Shrujal S Baxi
    Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Head Neck 35:1534-41. 2013
    ..Oropharyngeal cancers are increasingly associated with human papillomavirus (HPV). Little is known about the experience of patients receiving this diagnosis...
  18. doi request reprint A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 118:5008-14. 2012
    ..HNSCC tumors that express high levels of vascular endothelial growth factor have been associated with a worse prognosis, and bevacizumab may sensitize tumors to cisplatin and radiation...
  19. ncbi request reprint Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers
    Nancy Y Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 69:459-68. 2007
    ..To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT)...
  20. ncbi request reprint Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers
    Daniel R Gomez
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 73:1096-103. 2009
    ..To present our single-institution experience of intensity-modulated radiotherapy (IMRT) for oral cavity cancer...
  21. pmc Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial
    Richard L Bakst
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 80:148-53. 2011
    ..To evaluate the feasibility of dose-painting intensity-modulated radiation therapy (DP-IMRT) with a hypofractionated regimen to treat nasopharyngeal carcinoma (NPC) with concomitant toxicity reduction...
  22. ncbi request reprint TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome
    Eric J Sherman
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Laryngoscope 122:1043-50. 2012
    ..To develop and validate a simple prognostic tool that would help predict larynx preservation outcome...
  23. ncbi request reprint Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer
    Yungpo Bernard Su
    Department of a Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 12:182-8. 2006
    ..To evaluate the ability of granulocyte-stimulating factor to decrease mucositis during postoperative radiotherapy for stage II-IV squamous head and neck cancer in a randomized, double-blind, placebo-controlled trial...
  24. ncbi request reprint Postoperative complications of salvage total laryngectomy
    Ian Ganly
    Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:2073-81. 2005
    ....
  25. ncbi request reprint A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma
    Nancy Y Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 66:966-74. 2006
    ..intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma...
  26. doi request reprint A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 532, New York, NY 10021, USA
    Cancer Chemother Pharmacol 70:121-8. 2012
    ..The mammalian target of rapamycin complex 1 (mTORC1) is aberrantly activated in many head and neck squamous cell carcinomas (HNSCCs). This phase I study combines the mTORC1 inhibitor temsirolimus with carboplatin and paclitaxel...
  27. pmc Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome
    Ian Ganly
    Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Head Neck 33:1387-93. 2011
    ..The objective of this study was to determine the prognostic significance of viable tumor in postchemoradiation neck dissection specimens in patients with squamous cell carcinoma of the laryngopharynx...
  28. pmc Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases
    Jacobus F A Jansen
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 77:1403-10. 2010
    ....
  29. pmc Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anticancer Res 31:249-53. 2011
    ..Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC)...
  30. ncbi request reprint Causes of death in long-term survivors of head and neck cancer
    Shrujal S Baxi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York
    Cancer 120:1507-13. 2014
    ..Survivors of head and neck squamous cell carcinoma (HNSCC) face excess mortality from multiple causes...
  31. pmc Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue
    Neil M Iyengar
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:983-91. 2014
    ..Although obesity increases risk and negatively affects survival for many malignancies, the prognostic implications in squamous cell carcinoma (SCC) of the oral tongue, a disease often associated with prediagnosis weight loss, are unknown...
  32. doi request reprint Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer
    Anuj Goenka
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 133:1214-21. 2013
    ..We conclude that patients achieving CRs after chemoradiation, based on clinical and PET/CT assessment, have a high probability of regional control, with a 2.3% regional failure rate, and may be safely observed without planned ND...
  33. ncbi request reprint A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 25:165-72. 2007
    ..This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers...
  34. doi request reprint Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience
    Stephanie A Terezakis
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 73:795-801. 2009
    ..External beam radiotherapy (EBRT) plays a controversial role in the management of nonanaplastic thyroid cancer. We reviewed our institution's outcomes in patients treated with EBRT for advanced or recurrent nonanaplastic thyroid cancer...
  35. doi request reprint Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer
    Seng Chuan Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 49:532-40. 2008
    ..We investigated the clinical utility of 18F-FDG PET/CT in this setting...
  36. ncbi request reprint Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma
    William C Chen
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 106:820-9. 2006
    ..The incidence and severity of sensorineural hearing loss (SNHL) with combined modality therapy was evaluated and the dose-response relation between radiation and hearing loss was investigated...
  37. pmc Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, The Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:365-71. 2002
    ..6; 95% confidence interval = 1.9 to 29.6). The findings suggest that the 3q copy number status is an important marker for tumor progression and prognostication in patients with head and neck squamous cell carcinoma...
  38. ncbi request reprint A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer
    Alan L Ho
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, 300 E 66th Street, New York, NY, 10065, USA
    Invest New Drugs 32:549-54. 2014
    ..We conducted a phase II study of pralatrexate with folic acid and B12 supplementation in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC)...
  39. ncbi request reprint Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
    Radiother Oncol 101:425-30. 2011
    ..We evaluated our more recent experience with this approach, which included pathologic confirmation of all cases...
  40. ncbi request reprint Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent
    Iman Osman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2980-7. 2002
    ..To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent...
  41. ncbi request reprint A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    David G Pfister
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 20:123-7. 2002
    ..Further investigation is warranted to determine the strength of the correlation between bryostatin-1 activity and PARP cleavage as a surrogate molecular marker of apoptosis...
  42. pmc Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
    Alan L Ho
    Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 368:623-32. 2013
    ..In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium-iodide symporter and uptake of iodine. Their effects in humans are not known...
  43. pmc Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer
    Shrujal S Baxi
    Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Thyroid 22:552-5. 2012
    ..Here, we report a patient who developed a hemorrhagic abdominal pseudoaneurysm shortly after being started on this drug...
  44. ncbi request reprint Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 9:681-9. 2011
    ..Avenues for ongoing research are also presented...
  45. ncbi request reprint Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:57-62. 2006
    ..We now evaluate whether IMRT has resulted in improved outcomes for a larger cohort of patients with longer follow-up...
  46. ncbi request reprint A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Matthew G Fury
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Compr Canc Netw 10:1391-8. 2012
    ..Cetuximab, 500 mg/m(2), q2w achieves similar efficacy as conventional dosing for patients with recurrent or metastatic HNSCC. Escalating the dose to 750 mg/m(2) q2w offers no obvious therapeutic advantage...
  47. doi request reprint Molecular-targeted therapies in head and neck cancer
    Shyam D Rao
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Radiat Oncol 22:207-13. 2012
    ..In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation...
  48. doi request reprint Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
    Nancy Y Lee
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 13:172-80. 2012
    ..We aimed to improve the outcomes for locoregionally advanced nasopharyngeal carcinoma by testing the feasibility and safety of the addition of bevacizumab to chemoradiotherapy...
  49. ncbi request reprint A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 57:155-63. 2008
    ..Preclinical data suggest that co-administration of granulocyte-colony stimulating factor (G-CSF) may enhance the tumor cytotoxicity of bispecific antibodies...
  50. ncbi request reprint Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma
    Matthew G Fury
    Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Head Neck 33:1340-5. 2011
    ..The purpose of this study is to determine if p16 immunoreactivity is associated with aberrant expression of components of the PI3 kinase pathway...
  51. ncbi request reprint Using patients as their own controls for cost evaluation of phase I clinical trials
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1308-14. 2004
    ..Our objective was to utilize a new approach, using patients as their own controls, to compare in a pilot study the costs of care for patients on phase I trials with those incurred for standard treatment...
  52. ncbi request reprint A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  53. ncbi request reprint The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue
    Cherry L Estilo
    Dental Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:2300-6. 2003
    ..3 amplification. This study aimed to delineate the role of SCCRO and PIK3CA in the pathogenesis of oral tongue SCC...
  54. pmc 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 29:3825-31. 2011
    ..This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy...
  55. ncbi request reprint Value considerations in the treatment of head and neck cancer: radiation, chemotherapy, and supportive care
    Shrujal S Baxi
    From the Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weil Medical College of Cornell University, New York, NY Department of Radiation Oncology, Rush University Medical Center, Chicago, IL
    Am Soc Clin Oncol Educ Book 34:e296-303. 2014
    ..We review selected issues in radiotherapy, chemotherapy and supportive care applicable to the management of head and neck cancer and relevant to ascertaining the value of care. ..
  56. ncbi request reprint Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed
    Christopher G Azzoli
    J Natl Cancer Inst 99:828-9. 2007
  57. ncbi request reprint American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer
    David G Pfister
    American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
    J Clin Oncol 24:3693-704. 2006
    ..This guideline is intended for use by oncologists in the care of patients outside of clinical trials...
  58. ncbi request reprint American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
    Rowan T Chlebowski
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3328-43. 2002
    ..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide...
  59. ncbi request reprint Head and neck cancer: recent advances and new standards of care
    Arlene A Forastiere
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 24:2603-5. 2006
  60. ncbi request reprint Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge?
    Bhuvanesh Singh
    J Clin Oncol 26:3114-6. 2008
  61. ncbi request reprint Induction chemotherapy for larynx preservation: patient selection or therapeutic effect?
    David G Pfister
    J Clin Oncol 24:540-3. 2006
  62. ncbi request reprint Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline
    Christopher E Desch
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 23:8512-9. 2005
    ..To update the 2000 American Society of Clinical Oncology guideline on colorectal cancer surveillance...
  63. ncbi request reprint Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas
    Jacques Bernier
    Department of Radiation Oncology, Oncology Institute of Southern Switzerland, San Giovanni Hospital, CH 6504 Bellinzona, Switzerland
    Crit Rev Oncol Hematol 56:353-64. 2005
    ..There is remaining need for further research efforts that would enable scientists and clinicians to improve, in the next decade, the management of this complex entity of diseases...
  64. ncbi request reprint Skin squamous cell cancer: the time is right for greater involvement of the medical oncologist
    David G Pfister
    J Clin Oncol 25:1953-4. 2007
  65. ncbi request reprint American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003
    David G Pfister
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 22:330-53. 2004
  66. ncbi request reprint Head and neck cancers
    Arlene A Forastiere
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Natl Compr Canc Netw 3:316-91. 2005

Research Grants1

  1. Acupuncture for shoulder syndrome after ca surgery
    David Pfister; Fiscal Year: 2004
    ..Data: Standard deviations, mean of control group, correlation between and within baseline and follow-up measures. ..